anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Holmium laser enucleation of the prostate (HoLEP) is a surgical treatment option for benign prostatic hyperplasia (BPH). Many men develop retrograde ejaculation postprocedure, but there is conflicting evidence regarding sexual function outcomes post-HoLEP. We sought to examine significant variations in patient-reported erectile and ejaculatory function within 12 months post-HoLEP.
MATERIALS AND METHODS: We conducted a retrospective study for patients who underwent HoLEP between Nov 2018 and Feb 2022. Of the reviewed patients, 277 patients met inclusion criteria and completed pre and postoperative questionnaires, which included the Male Sexual Health Questionnaire- Ejaculatory Dysfunction (MSHQ-EJD) and the International Index of Erectile Function/Sexual Health Inventory for Men (IIEF-5/SHIM). Surveys were provided to patients up to 12 months postprocedure. Demographics and comorbidities associated with sexual dysfunction were collected. Responses to each question were analyzed to detect sub-categorical variations in sexual function as the secondary objective. Data was analyzed by using a linear mixed model.
RESULTS: There was a significant decline in total scores for the MSHQ-EJD (8.70 pre-HoLEP vs. 6.58 post HoLEP, p ≤ 0.001) including a significant decline (p < 0.005) in questions 1-3 which assess ejaculatory ability, strength, and volume. There was not a significant decline in question 4 which assesses bother (2.552 pre-HoLEP vs. 3.119 post-HoLEP, p = 0.526). There was not a significant decline in the IIEF-5/SHIM postoperatively (11.51 pre-HoLEP vs. 13.327 post-HoLEP, p = 0.498).
CONCLUSIONS: Patients undergoing HoLEP do not experience a decline in erectile function. Patients do experience a decline in ejaculatory function but did not find this bothersome.
Rural patients have poorer health indicators, including higher risk of developing osteoarthritis. The objective of this study is to compare rural patients undergoing primary total joint arthroplasty (TJA) at rural hospitals with those undergoing primary TJA at urban hospitals with regards to demographics, comorbidities, and complications and to determine the preferred location of care for rural patients. Data from the Healthcare Cost and Utilization Project National Inpatient Sample between 2016 and 2018 were analyzed. Demographics, comorbidities, inpatient complications, hospital length of stay, inpatient mortality, and discharge disposition were compared between rural patients who underwent TJA at rural hospitals and urban hospitals. Rural patients undergoing primary TJA in rural hospitals were more likely to be women, to be treated in the South, to have Medicaid payer status, to have dementia, diabetes mellitus, lung disease, and postoperative pulmonary complications, and to have a longer hospital length of stay. Those patients were also less likely to have baseline obesity, heart disease, kidney disease, liver disease, cancer, postoperative infection, and cardiovascular complications, and were less likely to be discharged home. Rural patients undergoing primary TJA tend to pursue surgery in their rural hospital when their comorbidity profile is manageable. These patients get their surgery performed in an urban setting when they have the means for travel and cost, and when their comorbidity profile is more complicated, requiring more specialized care, Rural patients are choosing to undergo their primary TJA in urban hospitals as opposed to their local rural hospitals. (Journal of Surgical Orthopaedic Advances 33(2):061-067, 2024).
<P>PROBLEM TO BE SOLVED: To provide a hair deforming agent which gives the treated hair good shine and manageability, a second agent for hair deformation constituting the hair deforming agent, and a method for hair deformation which gives the treated hair good shine and manageability.  <P>SOLUTION: The second agent for hair deformation includes at least a tetraester of pentaerythritol and a fatty acid and an oxidant. The hair deforming agent is composed of a first agent for hair deformation at least containing a reductant and the second agent for hair deformation. Preferably, the first agent for hair deformation further contain a solid wax or hydrocarbon at room temperature and an amino acid. The method for hair deformation employs the first agent for hair deformation and the second agent for hair deformation.  <P>COPYRIGHT: (C)2010,JPO&INPIT
NEW MATERIAL:A compound of the formula (Ac is acetyl). EXAMPLE:20-Acetoxyclavulone-2. USE:An anti-inflammatory agent having inhibitory action on multiplication of granulation tissues found in an experiment thereon which is a kind of assay of anti-inflammatory action. PREPARATION:A coal Clavularia viridis is roughly extracted with methanol, and the resultant extract in an aqueous system is concentrated and further extracted with ethyl acetate. The extract is subjected to the silica gel chromatography, and the adsorbed extract is extracted with a mixed solvent of benzene and ethyl acetate at 10:1 ratio. A fraction containing clavulones 1-3 is collected while searching for them by the thin layer chromatography. The resultant fraction is further searched for by changing the mixing ratio between the benzene and the ethyl acetate to 5:1 to afford the aimed compound of the formula.
Obesity is a global health issue that is intricately linked to the development and progression of chronic liver disease (CLD). This bidirectional connection, coupled with the obesity paradox (OP), presents a management dilemma. The established influence of obesity on the development and progression of chronic liver disease (CLD) is surpassed by the liver's impact on the onset and advancement of obesity. Patients with CLD always experience increased energy expenditure, reduced appetite, and low protein synthesis, all of which might lead to weight loss. However, metabolic disturbances, hormonal imbalances, inflammatory signaling, immobility, drugs, and alterations in nutrient metabolism can contribute to the development and exacerbation of obesity. Despite the propagation of the OP concept, none of the guidelines has changed, recommending being overweight. Research bias and confounders might be the lifebuoy explanation. Additionally, overlooking the lethal morbidities of obesity for survival benefits full of suffering seems to be an illogical idea. Therefore, rather than endorsing an overweight status, emphasis should be placed on improving cardiorespiratory fitness and preventing sarcopenia to achieve better outcomes in patients with CLD. Accordingly, the complex interplay between obesity, CLD, and the concept of OP requires a sophisticated individualized management approach. Maximizing cardiorespiratory fitness and mitigating sarcopenia should be considered essential strategies for attaining the most favourable outcomes in patients with chronic liver disease (CLD).
FORTAMET® was developed as an extended-release formulation of metformin hydrochloride and designed for once-a-day oral administration using the patented single-composition osmotic technology (SCOT™). The tablet is similar in appearance to other film-coated oral administered tablets but it consists of an osmotically active core formulation that is surrounded by a semipermeable membrane. Two laser drilled exit ports exist in the membrane, one on either side of the tablet. The core formulation is composed primarily of drug with small concentrations of excipients. The semipermeable membrane is permeable to water but not to higher molecular weight components of biological fluids. Upon ingestion, water is taken up through the membrane, which in turn dissolves the drug and excipients in the core formulation. The dissolved drug and excipients exit through the laser drilled ports in the membrane. The rate of drug delivery is constant and dependent upon the maintenance of a constant osmotic gradient across the membrane. This situation exists so long as there is undissolved drug present in the core tablet. Following the dissolution of the core materials, the rate of drug delivery slowly decreases until the osmotic gradient across the membrane falls to zero at which time delivery ceases. The membrane coating remains intact during the transit of the dosage form through the gastrointestinal tract and is excreted in the feces.
Clinical use of verapamil in digitalized patients has shown the combination to be well tolerated if digoxin doses are properly adjusted. Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. In patients with hepatic cirrhosis the influence of verapamil on digoxin kinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digitoxin by 27% and 29%, respectively. Maintenance digitalization doses should be reduced when verapamil is administered, and the patient should be carefully monitored to avoid over- or underdigitalization. Whenever overdigitalization is suspected, the daily dose of digitalis should be reduced or temporarily discontinued. Upon discontinuation of verapamil HCl use, the patient should be reassessed to avoid underdigitalization.
PURPOSE:To provide the subject blood platelet-anticoagulant containing bisdethiodimethylthioacetylapoaranotin as the active component, showing a remarkable platelet coagulation inhibition and effective for prevention and remedy of thrombosis. CONSTITUTION:A compound of the formula is contained as the active component. The above mentioned compound can be produced, e.g. by using Aspergillus terreus GSL-299 strain. The suitable amount of the above mentioned anticoagulant administrated is 5-300mg/kg in case of oral administration and 0.5-30mg/kg in case of parenteral administration. As the dosage form, tablet, powder, capsule, granule, suppository, injection, etc., can be used specifically.
FIELD: medicine. ^ SUBSTANCE: 1-3-fold amount of water is added to mixed five-seven-year old ginseng with further treatment at pressure 1.20 to 1.50 kg/cm2 if ginseng is rind, or 2.30 to 3.00 kg/cm2 if ginseng is covered with rind at 110-130C during 1 to 5 hours to produce treated ginseng thereafter extracted with mixed methanol and methylene chloride in ratio 0.6:1.40 to 1.2:0.8 by boiling extraction method with using a backflow condenser during 1 hour to approximately two days. The mixture is filtered that is followed with filtrate concentration and drying. The pharmaceutical composition for treatment or prevention of stomach, liver, lung, skin or breast cancer contains ginseng extract. Foodstuff contains ginseng extract. ^ EFFECT: product with high content of ginsenoside Rg5. ^ 6 cl, 3 ex, 3 tbl, 14 dwg
The present invention relates to an oligonucleotide comprising one of the following sequence: (TTAGGG) SEQ ID No. 1, (TAGGGT) SEQ ID No. 2, (AGGGTT) SEQ ID No. 3, (GGGTTA) SEQ ID No. 4, (GGTTAG) SEQ ID No. 5 or (GTTAGG) SEQ ID No. 6 or a complementary sequence thereof or a fragment or a variant or a mixture thereof for use in the treatment and/or prevention of a disease characterized by alternative lengthening of telomeres or a non-cancer condition associated with telomere dysfunction and relative pharmaceutical compositions and to relative pharmaceutical composition and method.
BACKGROUND & AIMS: Polyploidy in hepatocytes has been proposed as a genetic mechanism to buffer against transcriptional dysregulation. Here, we aim to demonstrate the role of polyploidy in modulating gene regulatory networks in hepatocytes during ageing.
METHODS: We performed single-nucleus RNA sequencing in hepatocyte nuclei of different ploidy levels isolated from young and old wild-type mice. Changes in the gene expression and regulatory network were compared to three independent strains that were haploinsufficient for HNF4A, CEBPA or CTCF, representing non-deleterious perturbations. Phenotypic characteristics of the liver section were additionally evaluated histologically, whereas the genomic allele composition of hepatocytes was analysed by BaseScope.
RESULTS: We observed that ageing in wild-type mice results in nuclei polyploidy and a marked increase in steatosis. Haploinsufficiency of liver-specific master regulators (HFN4A or CEBPA) results in the enrichment of hepatocytes with tetraploid nuclei at a young age, affecting the genomic regulatory network, and dramatically suppressing ageing-related steatosis tissue wide. Notably, these phenotypes are not the result of subtle disruption to liver-specific transcriptional networks, since haploinsufficiency in the CTCF insulator protein resulted in the same phenotype. Further quantification of genotypes of tetraploid hepatocytes in young and old HFN4A-haploinsufficient mice revealed that during ageing, tetraploid hepatocytes lead to the selection of wild-type alleles, restoring non-deleterious genetic perturbations.
CONCLUSIONS: Our results suggest a model whereby polyploidisation leads to fundamentally different cell states. Polyploid conversion enables pleiotropic buffering against age-related decline via non-random allelic segregation to restore a wild-type genome.
IMPACT AND IMPLICATIONS: The functional role of hepatocyte polyploidisation during ageing is poorly understood. Using single-nucleus RNA sequencing and BaseScope approaches, we have studied ploidy dynamics during ageing in murine livers with non-deleterious genetic perturbations. We have identified that hepatocytes present different cellular states and the ability to buffer ageing-associated dysfunctions. Tetraploid nuclei exhibit robust transcriptional networks and are better adapted to genomically overcome perturbations. Novel therapeutic interventions aimed at attenuating age-related changes in tissue function could be exploited by manipulation of ploidy dynamics during chronic liver conditions.
The application relates to the field of antibodies, in particular to a coxsackievirus A10 monoclonal antibody and application thereof. The A10 monoclonal antibody comprises one or more of the following technical characteristics: the heavy chain variable region comprises CDR-H1 with an amino acid sequence shown as SEQ ID No. 1; the heavy chain variable region comprises CDR-H2 with an amino acid sequence shown as SEQ ID No. 2; the heavy chain variable region comprises CDR-H3 with an amino acid sequence shown as SEQ ID No. 3; the light chain variable region comprises CDR-L1 with an amino acid sequence shown as SEQ ID No. 4; the light chain variable region comprises CDR-L2 with an amino acid sequence shown as SEQ ID No. 5; the light chain variable region comprises CDR-L3 of the amino acid sequence shown in SEQ ID No. 6. Through screening detection, a monoclonal antibody which can specifically bind to A10 and has neutralization activity is obtained: 10H 11. The 10H11 can be used for developing antiviral drugs of CV A10, and can be used as a high-efficiency sensitive detection reagent in clinical diagnosis of A10 infection, an A10 vaccine screening and qualitative and quantitative detection and detection reagent of vaccine antigens, and an antibody reference for evaluating the activity of the A10 vaccine.
BACKGROUND: Immune and inflammatory factors are considered the basic underlying mechanisms of IgA nephropathy (IgAN). The systemic immune inflammation index (SII) is a new inflammatory biomarker and has been identified as a prognostic indicator for various diseases. However, limited studies have been conducted on the prognostic value of the SII in patients with IgAN, and we aimed to address this gap.
METHODS: A total of 374 patients with IgAN confirmed by renal biopsy performed from 1 January 2015 to 1 April 2019, were retrospectively included. The follow-up period of all patients was at least 12 months after diagnosis, and the endpoint was defined as end-stage kidney disease (ESKD). Patients were further divided into a high-risk group (SII ≥ 456.21) and a low-risk group (SII < 456.21) based on the optimal cutoff value of the SII determined by receiver operating characteristic (ROC) curve analysis. Baseline clinicopathological parameters were compared between the groups, and Cox proportional hazards analyses and Kaplan-Meier analysis were performed to assess renal survival in IgAN patients.
RESULTS: After a median follow-up period of 32.5 months, a total of 53 patients eventually reached ESKD. Patients in the high-SII group tended to have a lower hemoglobin level (p = 0.032) and eGFR (p < 0.001), a higher serum creatinine level (p = 0.023) and 24-hour total protein level (p = 0.004), more severe tubular atrophy and interstitial fibrosis (p = 0.002) and more crescents (p = 0.030) than did those in the low-SII group. Univariate and multivariate Cox regression analyses demonstrated that an SII ≥456.21 was an independent risk factor for poor renal survival in IgAN patients (HR 3.028; 95% CI 1.486-6.170; p = 0.002). Kaplan-Meier analysis revealed that a high SII was significantly associated with poor renal prognosis (p < 0.001) and consistently exhibited remarkable discriminatory ability across different subgroups in terms of renal survival.
CONCLUSION: A high SII was associated with more severe baseline clinical and pathological features, and an SII ≥456.21 was an independent risk factor for progression to ESKD in IgAN patients.
Bone aging is characterized by an imbalance in the physiological and pathological processes of osteogenesis, osteoclastogenesis, adipogenesis, and chondrogenesis, resulting in exacerbated bone loss and the development of age-related bone diseases, including osteoporosis, osteoarthritis, rheumatoid arthritis, and periodontitis. Inflammaging, a novel concept in the field of aging research, pertains to the persistent and gradual escalation of pro-inflammatory reactions during the aging process. This phenomenon is distinguished by its low intensity, systemic nature, absence of symptoms, and potential for management. The mechanisms by which inflammaging contribute to age-related chronic diseases, particularly in the context of age-related bone diseases, remain unclear. The precise manner in which systemic inflammation induces bone aging and consequently contributes to the development of age-related bone diseases has yet to be fully elucidated. This article primarily examines the mechanisms underlying inflammaging and its association with age-related bone diseases, to elucidate the potential mechanisms of inflammaging in age-related bone diseases and offer insights for developing preventive and therapeutic strategies for such conditions.
Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level.

The primary source of estrogen in normally cycling adult women is the ovarian follicle, which secretes 70 to 500 mcg of estradiol daily, depending on the phase of the menstrual cycle. After menopause, most endogenous estrogen is produced by conversion of androstenedione, secreted by the adrenal cortex, to estrone in the peripheral tissues. Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women. 

Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. To date, two estrogen receptors have been identified. These vary in proportion from tissue to tissue.

Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.
Embodiments of the present invention are directed to a method and apparatus for automatic health monitoring. In one embodiment, a regularly accessed device is equipped with an access detection unit. In one embodiment, a regularly accessed device is a temperature controlled compartment. In one embodiment, a timer is started when the access detection unit detects an access to the temperature controlled compartment. In one embodiment, a determination unit determines whether a second access is made within a time interval of a first access. In one embodiment, the time interval is determined using the patient's recommended medication regimen. In one embodiment, when a determination unit determines that a second access is not made within a time interval of a first access, a signal generator generates a signal. In one embodiment, the signal is transmitted to a healthcare provider. In one embodiment, the signal is transmitted via a computer network.
<P>PROBLEM TO BE SOLVED: To provide a method which is for targeting a therapeutic agent on a cellular partition and which is novel, more simple, more efficient, and more costly effective.  <P>SOLUTION: By providing a targeted protein therapeutic agent for localizing cells requiring a therapeutic agent in a subcellular partition, the treatment of metabolic disorder is facilitated. By decreasing the necessity of processing after translation or processing after elaboration of the protein, the preparation of the targeting protein therapeutic agent is simplified. By this invention, a targeting therapeutic agent, such as lysosome, locally existing in a subcellular partition is provided. The targeting therapeutic agent includes a therapeutic drug and a target-nature portion bonded to a receptor on the outside surface of a cell, and in internalization of the receptor, suitable subcellular localization of the targeting therapeutic agent is enabled. Nucleic acid, a cell, and the method are also provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
No intervention was delivered. At baseline, participants completed eligibility and baseline surveys. Follow-up data was collected 4-6 months post-baseline survey.
Lisdexamfetamine is a prodrug of dextroamphetamine. After oral administration, lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and converted primarily in blood due to the hydrolytic activity of red blood cells to dextroamphetamine, which is responsible for the drug's activity. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. The parent drug, lisdexamfetamine, does not bind to the sites responsible for the reuptake of norepinephrine and dopamine in vitro.